Variants at the Endocannabinoid Receptor CB1 Gene (CNR1) and Insulin Sensitivity, Type 2 Diabetes, and Coronary Heart Disease

[1]  Rodolfo Montironi,et al.  Cannabinoid CB1 receptor expression in relation to visceral adipose depots, endocannabinoid levels, microvascular damage, and the presence of the Cnr1 A3813G variant in humans. , 2010, Metabolism: clinical and experimental.

[2]  Christian Gieger,et al.  New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk , 2010, Nature Genetics.

[3]  D. Goldstein.  Common genetic variation and human traits. , 2009, The New England journal of medicine.

[4]  S. Kathiresan,et al.  Glycated albumin and direct low density lipoprotein cholesterol levels in type 2 diabetes mellitus. , 2009, Clinica chimica acta; international journal of clinical chemistry.

[5]  S. Woods,et al.  Food Intake‐independent Effects of CB1 Antagonism on Glucose and Lipid Metabolism , 2009, Obesity.

[6]  V. Fonseca,et al.  Emerging concepts in the pathophysiology of type 2 diabetes mellitus. , 2009, The Mount Sinai journal of medicine, New York.

[7]  J. Florez,et al.  Genetic Architecture of Type 2 Diabetes: Recent Progress and Clinical Implications , 2009, Diabetes Care.

[8]  R. Vasan,et al.  Variants in the CNR1 and the FAAH Genes and Adiposity Traits in the Community , 2009, Obesity.

[9]  F. Bermúdez-Silva,et al.  The role of the pancreatic endocannabinoid system in glucose metabolism. , 2009, Best practice & research. Clinical endocrinology & metabolism.

[10]  C. Bouchard,et al.  Association between insulin secretion, insulin sensitivity and type 2 diabetes susceptibility variants identified in genome-wide association studies , 2009, Acta Diabetologica.

[11]  M. Olivier,et al.  Genetic variation in cannabinoid receptor 1 (CNR1) is associated with derangements in lipid homeostasis, independent of body mass index. , 2008, Pharmacogenomics.

[12]  R. D'Agostino,et al.  Genotype score in addition to common risk factors for prediction of type 2 diabetes. , 2008, The New England journal of medicine.

[13]  A. Cecile J.W. Janssens,et al.  Predicting Type 2 Diabetes Based on Polymorphisms From Genome-Wide Association Studies , 2008, Diabetes.

[14]  J. Rosenstock,et al.  SERENADE: The Study Evaluating Rimonabant Efficacy in Drug-Naive Diabetic Patients , 2008, Diabetes Care.

[15]  M. Hutz,et al.  Cannabinoid Type-1 Receptor Gene Polymorphisms Are Associated with Central Obesity in a Southern Brazilian Population , 2008, Disease markers.

[16]  R. Pratley,et al.  The cannabinoid CB1 receptor is expressed in pancreatic delta-cells. , 2008, Biochemical and biophysical research communications.

[17]  T. McGraw,et al.  The CB1 Endocannabinoid System Modulates Adipocyte Insulin Sensitivity , 2008, Obesity.

[18]  T. Hansen,et al.  Endocannabinoid receptor 1 gene variations increase risk for obesity and modulate body mass index in European populations. , 2008, Human molecular genetics.

[19]  J. Florez.  Newly identified loci highlight beta cell dysfunction as a key cause of type 2 diabetes: Where are the insulin resistance genes? , 2008, Diabetologia.

[20]  Deepak L. Bhatt,et al.  Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. , 2008, JAMA.

[21]  F. Bermúdez-Silva,et al.  Presence of functional cannabinoid receptors in human endocrine pancreas , 2008, Diabetologia.

[22]  K. Sirotkin,et al.  The NCBI dbGaP database of genotypes and phenotypes , 2007, Nature Genetics.

[23]  W. Hul,et al.  The G1422A variant of the cannabinoid receptor gene (CNR1) is associated with abdominal adiposity in obese men , 2007, Endocrine.

[24]  M. McCarthy,et al.  Replication of Genome-Wide Association Signals in UK Samples Reveals Risk Loci for Type 2 Diabetes , 2007, Science.

[25]  Marcia M. Nizzari,et al.  Genome-Wide Association Analysis Identifies Loci for Type 2 Diabetes and Triglyceride Levels , 2007, Science.

[26]  D. Tregouet,et al.  Genetic variations at the endocannabinoid type 1 receptor gene (CNR1) are associated with obesity phenotypes in men. , 2007, The Journal of clinical endocrinology and metabolism.

[27]  T. Meitinger,et al.  No evidence for an involvement of variants in the cannabinoid receptor gene (CNR1) in obesity in German children and adolescents. , 2007, Molecular genetics and metabolism.

[28]  P. Löfgren,et al.  Human adipose tissue cannabinoid receptor 1 gene expression is not related to fat cell function or adiponectin level. , 2007, The Journal of clinical endocrinology and metabolism.

[29]  V. Marzo,et al.  Endocannabinoids and the control of energy balance , 2007, Trends in Endocrinology & Metabolism.

[30]  M. Jensen,et al.  Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study , 2006, The Lancet.

[31]  J. Després,et al.  Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. , 2005, The New England journal of medicine.

[32]  Arya M. Sharma,et al.  Activation of the peripheral endocannabinoid system in human obesity. , 2005, Diabetes.

[33]  M. Permutt,et al.  Genetic epidemiology of diabetes. , 2005, The Journal of clinical investigation.

[34]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[35]  K. Sharkey,et al.  Cannabinoid (CB)1 receptor antagonist, AM 251, causes a sustained reduction of daily food intake in the rat , 2004, Physiology & Behavior.

[36]  G. Uhl,et al.  Human cannabinoid receptor 1: 5′ exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse , 2004, Molecular Psychiatry.

[37]  P. Soubrié,et al.  CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity , 2004, International Journal of Obesity.

[38]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[39]  The Procardis Consortium.  A trio family study showing association of the lymphotoxin-α N26 (804A) allele with coronary artery disease , 2004, European Journal of Human Genetics.

[40]  M. Herkenham,et al.  International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors , 2002, Pharmacological Reviews.

[41]  D. Schaid.  Mathematical and Statistical Methods for Genetic Analysis , 1999 .

[42]  P. Poulsen,et al.  Heritability of Type II (non-insulin-dependent) diabetes mellitus and abnormal glucose tolerance – a population-based twin study , 1999, Diabetologia.

[43]  L. Almasy,et al.  Multipoint quantitative-trait linkage analysis in general pedigrees. , 1998, American journal of human genetics.

[44]  Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-94. Series 1: programs and collection procedures. , 1994, Vital and health statistics. Ser. 1, Programs and collection procedures.

[45]  W. Kannel,et al.  An investigation of coronary heart disease in families. The Framingham offspring study. , 1979, American journal of epidemiology.